Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lewis

Showing results (1151-1160 of 1,275) with videos related to

Pageof 128
Sort By:
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
Cell|November 15, 1996
The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivoQ Wang, T Stacy, J D Miller, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
JACC. Heart Failure|October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trialsAlberto Foà, Maria A Pabon, Eugene Braunwald, et al.
European Journal of Heart Failure|December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Journal of Heart Failure|July 26, 2024
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MIFinnian R Mc Causland, Martina M McGrath, Brian L Claggett, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Long-term Penetrance of Disease Variants in Genes Prioritized for Genomic Newborn Screening: Evidence from Adult BiobanksNina B Gold, Hana Zouk, Julie Yeo, et al.
Journal of the American College of Cardiology|January 6, 2026
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical TrialsPablo M Marti-Castellote, Samarra Badrouchi, Brian Claggett, et al.
Pageof 128

Showing results (1151-1160 of 1,275) with videos related to

Sort By:
Pageof 128
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
Cell|November 15, 1996
The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivoQ Wang, T Stacy, J D Miller, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
JACC. Heart Failure|October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trialsAlberto Foà, Maria A Pabon, Eugene Braunwald, et al.
European Journal of Heart Failure|December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Journal of Heart Failure|July 26, 2024
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MIFinnian R Mc Causland, Martina M McGrath, Brian L Claggett, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Long-term Penetrance of Disease Variants in Genes Prioritized for Genomic Newborn Screening: Evidence from Adult BiobanksNina B Gold, Hana Zouk, Julie Yeo, et al.
Journal of the American College of Cardiology|January 6, 2026
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical TrialsPablo M Marti-Castellote, Samarra Badrouchi, Brian Claggett, et al.
Pageof 128